BNR Stock Overview
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China.
Burning Rock Biotech Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.54|
|52 Week High||US$14.00|
|52 Week Low||US$1.70|
|1 Month Change||20.95%|
|3 Month Change||-18.33%|
|1 Year Change||-79.28%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-89.69%|
Recent News & Updates
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?Sep 20
We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash WiselyMar 24
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?Aug 27
A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)Jul 23
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?May 13
|BNR||US Biotechs||US Market|
Return vs Industry: BNR underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: BNR underperformed the US Market which returned -14.9% over the past year.
|BNR Average Weekly Movement||12.4%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: BNR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: BNR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Burning Rock Biotech Limited Fundamentals Summary
|BNR fundamental statistics|
Is BNR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BNR income statement (TTM)|
|Cost of Revenue||CN¥184.19m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-9.57|
|Net Profit Margin||-177.03%|
How did BNR perform over the long term?See historical performance and comparison